Method for producing insulin-producing β-cells
By employing butyrate during key stages of β-cell differentiation in a three-dimensional culture, the method enhances insulin secretion capacity in insulin-producing β-cells, addressing the inefficiencies of existing methods.
Patent Information
- Application Number
- JP2025078289
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-08
- Publication Date
- 2026-11-19
AI Technical Summary
Existing methods for producing insulin-producing β-cells from stem cells result in cells that secrete less insulin than human pancreatic islets, and the role of short-chain fatty acids (SCFAs) in human pluripotent cell differentiation is not fully understood.
A method involving the use of butyrate during specific stages of differentiation to mature immature insulin-expressing β-cells, particularly in a three-dimensional culture, enhances glucose-stimulated insulin secretion (GSIS) capacity.
The method produces insulin-producing β-cells with improved insulin secretion capacity, achieving significant insulin secretion at glucose concentrations of 20 mM or more.
Smart Images

Figure 2026182235000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to a method for producing insulin-producing β-cells. [Background technology]
[0002] Transplantation of stem cell-derived β-cells (SC-β) presents a promising approach to treating diabetes, relying on high differentiation efficiency and robust functional maturation. Our previous studies demonstrated that short-term deficiency of reducing methionine and zinc before differentiation enhances pancreatic differentiation efficiency (Non-Patent Literature 1; Non-Patent Literature 2; Non-Patent Literature 3).
[0003] On the other hand, previous studies have revealed that short-chain fatty acids (SCFAs) play an important role in regulating cell differentiation. Specifically, butyrate has been observed to promote differentiation in a two-dimensional endoderm differentiation system used for pluripotent stem cells (Non-Patent Literature 4). Regarding pancreatic differentiation, it has been suggested that butyrate promotes differentiation into exocrine pancreatic cells after embryoid body formation during the development of mouse embryonic stem cells (Non-Patent Literature 5). Furthermore, in nestin-positive progenitor cells derived from mouse pancreas, it has been established that butyrate does not show any effect when administered alone, but it amplifies the effect of GLP-1 on pancreatic differentiation (Non-Patent Literature 6). However, the precise roles of butyrate and other SCFAs in human pluripotent cells have not yet been elucidated. [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Shiraki , N. , Shiraki , Y. , Tsuyama , T. , Obata , F. , Miura , M. , Nagae , G. , Aburatani , H. , Kume , K. , Endo , F. , and Kume , S. (2014). Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell Metab 19, 780–794.
Outdoor Tool2
Outdoor Tools3
Outdoor Tools 4
[0005] The present invention aims to provide a method for producing insulin-producing β-cells. [Means for solving the problem]
[0006] To overcome the problem that β-cells differentiated in vitro secrete less insulin than human pancreatic islets, the inventors focused on metabolites derived from the gut microbiota, which are components present in the body but not in the culture medium, and aimed to achieve cell differentiation under conditions closer to normal development. The main metabolites of the gut microbiota are short-chain fatty acids (SCFAs), mainly butyrate, propionic acid, and acetic acid. The inventors investigated the effects of SCFAs on both human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), and evaluated their effects on cell proliferation, differentiation, and insulin secretion. More specifically, they evaluated the effects of SCFAs, particularly acetic acid, propionic acid, and butyrate, on SC-β differentiation at key stages such as endodermal formation (stage 1), pancreatic progenitor cell differentiation (stage 4), and endocrine system maturation (stage 6). As a result, we found that the addition of butyrate in stage 1 inhibited differentiation from hESC cells to endoderm and caused cell death, but not in hiPSC cells, indicating a difference between cell lines. Furthermore, when butyrate was added in stage 4, cells differentiated into β cells, but glucose-stimulated insulin secretion (GSIS) ability was lost. Notably, supplementing with butyrate in stage 6 significantly enhanced GSIS. In contrast, acetate and propionic acid did not show any beneficial effect on GSIS in stage 6. This invention was completed based on these findings.
[0007] The gist of this invention is as follows: (1) A method for producing insulin-producing β-cells, The method comprising bringing immature insulin-expressing β-cells into contact with butyrate to induce maturation into insulin-producing β-cells. (2) Insulin-producing β-cells have improved insulin secretion capacity compared to immature β-cells (as described in (1)). (3) The method according to claim 1 or 2, wherein immature β cells expressing insulin are differentiated from pluripotent stem cells. (4) The method according to (3), wherein the pluripotent stem cells are ES cells and / or iPS cells. (5) The method according to any of (1) to (3), wherein the immature β-cells expressing insulin are of human origin. (6) The method according to any of (1) to (5), wherein immature β cells expressing insulin are cultured in a butyrate-containing medium. (7) The method described in (6) wherein the culture is a three-dimensional culture. (8) Insulin-producing β-cells prepared by any of the methods described in (1) to (7), which can secrete C-peptide at a glucose concentration of 20 mM or more. (9) A culture medium for maturing immature β cells into insulin-producing β cells, the culture medium containing butyric acid. [Effects of the Invention]
[0008] The present invention provides a method for producing insulin-producing β-cells. [Brief explanation of the drawing]
[0009] [Figure 1] Effect of SCFAs on differentiation efficiency during the developmental stages of hESC-derived pancreatic β-cells. A) Experimental timeline of SCFA treatment in pancreatic differentiation. Using MEL1 INSGFP / whESCs, 1 mM butyrate, 1 mM propionic acid, and 1 mM acetic acid were added at stages 1, 4, and 6, and evaluations were performed at the end of each stage. In stages 1-5, 3D rotational culture was performed using a low-cell-binding 6-well plate, and in stage 6, 3D static culture was performed using a microcavity 24-well plate. B) Results of SCFA treatment at stage 1 on endodermal differentiation. Spheroid morphology (left) and the percentage of embryonic endoderm in SOX17+ / OCT4- are shown (right). Scale bar: 200 μm. C) Effect of SCFA addition at stages 1 and 4 on the differentiation of PDX1+ / NKX6.1+ endocrine progenitor cells. D) Improvement of C-peptide+ / Nkx6.1+ pancreatic β-cell differentiation after stage 6 treatment with 1 mM butyrate. Data are presented as mean ± SD. N = 3. Differences between groups were analyzed using Dunnett's multiple comparison test after a standard one-way ANOVA. Significant differences between groups are indicated by ** p < 0.01, *** p < 0.001, and *** p < 0.0001. [Figure 2] Functional and morphological effects of butyrate treatment on pancreatic β-cell differentiation of late-stage hiPSCs by 3D rotational culture. A) Schematic diagram of SCFA treatment in pancreatic differentiation. RPChiPS7713G1hiPSCs were used, and 1 mM butyrate, 1 mM propionic acid, and 1 mM acetate were added at stage 6, followed by evaluation on day 31. A 5-hour methionine-deficient pretreatment was performed before early differentiation. 3D rotational culture was performed using low-cell-binding 6-well plates at all differentiation stages. B) Sphere aggregation is induced by differences in the timing of 1 mM butyrate supplementation. The results of SCFA treatment at stage 6 in pancreatic β-cell differentiation are shown in spheroid morphology (upper panel, scale bar: 500 μm) and immunocytochemical images of C-peptide+ / Nkx6.1+ β-cells (lower panel, scale bar: 200 μm). C) Immunocytochemical analysis of β-cell markers C-peptide and Nkx6.1 after SCFA addition at stage 6. D) Enhancement of GSIS by butyrate administration in stage 6. The GSIS capacity of cells in each experimental group was evaluated by quantifying the amount of C-peptide secreted per minute for 1,000 cells. E) Quantitative PCR analysis showing the decrease in insulin mRNA expression due to butyrate treatment. The values were calculated as a relative scale by dividing the insulin expression level normalized by β-actin in each group by that of the control group. F) Dose-dependent effect of butyrate on insulin secretion in stage 6. The effect of adding 0.1 mM or 1 mM butyrate on GSIS was evaluated using stage 5 human iPS cell-derived pancreatic cells. 1 mM butyrate significantly promoted insulin secretion in both the low glucose (3 mM) and high glucose (20 mM) groups, but 0.1 mM butyrate had no effect. Data are shown as mean ± SD. N = 3. Differences between groups were analyzed using Dunnett's multiple comparison test after a standard one-way ANOVA. Significant differences between groups were indicated by * p < 0.05, ** p < 0.01, and *** p < 0.001. [Figure 3]Verification of butyrate-induced functional enhancement at differentiation stage 6 of hiPSC-derived pancreatic β cells. Experimental schema for verifying the effect of SCFAs administration at stage 4 and stage 6. RPChiPS7713G1 hiPSCs were used. For butyric acid, two groups were set up, each supplemented with 1 mM at either stage 4 or stage 6. Meanwhile, for propionic acid and acetic acid, 1 mM was supplemented only at stage 4, and each was tested in one group. The GSIS assay was performed on day 31. B) Consistent enhancement of C-peptide secretion by butyrate supplementation at stage 6 under both low-glucose and high-glucose conditions, and lack of effect at stage 4. Data are presented as mean ± SD. N = 3. Differences between groups were analyzed using ordinary one-way ANOVA and Dunnett's multiple comparisons test. Significant differences between groups are indicated by *** p < 0.001. [Mode for Carrying Out the Invention]
[0010] Hereinafter, the present invention will be described in detail.
[0011] The present invention provides a method for producing insulin-producing β cells, comprising bringing immature β cells that express insulin into contact with butyric acid to mature the immature β cells into insulin-producing β cells.
[0012] In the present invention, immature β cells that express insulin are brought into contact with butyric acid to mature into insulin-producing β cells.
[0013] As used herein, the term "insulin-producing β cell" means a β cell that secretes insulin in response to an insulin secretion-promoting substance and hyperglycemia, and has a significantly superior insulin expression capacity compared to other pancreatic hormones. Examples of other pancreatic hormones here include glucagon and somatostatin. Functionally, β cells sense an increase in extracellular glucose concentration and respond to ATP-sensitive K +Channel closure, voltage-gated Ca 2+ Channel opening, Ca 2+ It possesses a secretory mechanism that exocytoses insulin granules after influx. It is characterized by expressing molecular markers such as the insulin gene product and C-peptide, as well as PDX1, NKX6.1, and MAFA. In this invention, "β-cells" include not only those naturally occurring in the bodies of mammals (including humans), but also cells induced and amplified in vitro by iPS cells, ES cells, somatic cell transdifferentiation, and genetically modified cell lines.
[0014] In this specification, "immature β-cells" refer to cells that express insulin but have insufficient function, such as insulin secretion capacity. The expression of markers may be C-peptide+ / NKX6.1+ and insulin+ / glucagon- / somatostatin-. When immature β-cells are matured, their function, such as insulin secretion capacity, improves, and they may also express UCN3 and MAFA, which are mature β-cell markers. Insulin-producing β-cells produced by the method of the present invention may have improved insulin secretion capacity compared to immature β-cells.
[0015] Immature β-cells expressing insulin can be differentiated from pluripotent stem cells. Furthermore, immature β-cells expressing insulin can be differentiated from mesenchymal stem cells or pancreatic progenitor cells produced by direct reprogramming. Ideally, these insulin-expressing immature β-cells should be of human origin.
[0016] In this specification, when the terms "manufacture" or "production" are used with the intention of producing insulin-producing β-cells, they may be replaced with "differentiation (induction)," and unless otherwise specified, these terms are used interchangeably.
[0017] In this specification, "pluripotent stem cells" refers to cells that have the ability to self-renew, can be cultured in vitro, and have the multipotency to differentiate into cells that constitute an individual. Specifically, examples include embryonic stem cells (ES cells), pluripotent stem cells derived from fetal primordial germ cells (GS cells), induced pluripotent stem cells (iPS cells) derived from somatic cells, and somatic stem cells. However, iPS cells or ES cells are preferably used in the present invention, and human iPS cells and human ES cells are particularly preferred.
[0018] Pluripotent stem cells can be cultured and maintained using methods commonly employed in this field.
[0019] Mammalian-derived ES cells can be cultured using conventional methods. For example, mouse fetal fibroblasts (MEF cells) can be used as feeder cells, and the cells can be maintained in a culture medium such as DMEM medium, which contains leukemia inhibitors, KSR (knockout serum substitute), fetal bovine serum (FBS), non-essential amino acids, L-glutamine, pyruvate, penicillin, streptomycin, and β-mercaptoethanol.
[0020] iPS cells can also be cultured using standard methods. For example, MEF cells can be used as feeder cells and maintained in a medium containing bFGF, KSR (knockout serum substitute), non-essential amino acids, L-glutamine, penicillin, streptomycin, and β-mercaptoethanol, such as DMEM / F12 medium.
[0021] Both ES cells and iPS cells may be cultured under feeder-free conditions on cell culture dishes pre-coated with vitronectin using human iPSC maintenance medium StemFit AK02N (Ajinomoto). After thawing the ESCs / iPSCs in the dish, it is advisable to add the Rho-associated kinase (ROCK) inhibitor Y-27632 to the medium for 24 hours to prevent apoptosis.
[0022] In the method of the present invention, immature β-cells expressing insulin are preferably cultured in a butyrate-containing medium. Three-dimensional culture is preferable. "Three-dimensional culture" refers to a culture form in which cells are arranged three-dimensionally, maintaining cell-cell or cell-extracellular matrix interactions in a three-dimensional manner. This includes spheroid formation, hydrogel encapsulation, or porous scaffold seeding, and the method itself is not particularly limited. Three-dimensional culture improves differentiation induction efficiency and maturity, allowing for the production of highly pure and large quantities of functional insulin-producing β-cells compared to two-dimensional culture. Furthermore, rotational culture is preferable. In the examples described later, differentiation into β-cells was performed by rotational culture at 95 rpm using a horizontal rotation type rotary shaker. However, the present invention is not limited to this, and other rotational culture devices, including bioreactors with stirring blades, may be used. Culture conditions such as the type of device, rotation (or stirring) speed, angle, and packing rate can be appropriately changed depending on the cell type, spheroid diameter, and scale. Three-dimensional rotational culture allows for mass production of cells. Spheres are formed by three-dimensional cell culture. The sphere size is often 100 to 600 m in diameter, preferably 200 to 500 m. The sphere size can be adjusted by the rotation speed during culture. The rotation speed is often 80 to 120 rpm, preferably 85 to 110 rpm.
[0023] Insulin-producing β-cells can be differentiated from pluripotent stem cells through the following stages 1 to 6. In one embodiment of the present invention, butyrate may be added to the culture medium in stage 6 below.
[0024] Stage 1 (Endoderm Formation): Pluripotent stem cells are induced to differentiate into definitive endoderm cells.
[0025] Pluripotent stem cells are cultured in a medium containing activin receptor-like kinase-4,7 activators (e.g., Activin-A), a GSK3 inhibitor (e.g., CHIR99021), and a Rock inhibitor (e.g., Y27632). On days 1 and 2, the medium is replaced with the same medium but without the GSK3 inhibitor and Rock inhibitor. If the pluripotent stem cells are iPS cells, a methionine-deficient pretreatment of 3-8 hours (e.g., 5 hours) is recommended before initial differentiation. In this specification, "methionine-deficient pretreatment" refers to the process of culturing the stem cells for approximately 5 hours in an undifferentiated maintenance medium for pluripotent stem cells that is substantially free of methionine (methionine concentration of approximately 0-1 μM, including below the detection limit), and then quickly replacing it with a differentiation induction medium to continue culturing. This pretreatment improves the differentiation efficiency to the target lineage in the subsequent differentiation induction process and reduces variability in differentiation ability among cell lines. The culture time can be changed as appropriate.
[0026] The concentration of the activin receptor-like kinase-4,7 activator (e.g., Activin-A) in the culture medium is preferably 25 to 1000 ng / mL, more preferably 50 to 500 ng / mL, and more preferably 100 to 200 ng / mL.
[0027] The concentration of the GSK3 inhibitor (e.g., CHIR99021) in the culture medium is preferably 0.1 to 10 μM, more preferably 0.5 to 5 μM, and more preferably 2 to 4 μM.
[0028] The concentration of the Rock inhibitor (e.g., Y27632) in the culture medium is preferably 0.5 to 50 μM, more preferably 1 to 20 μM, and more preferably 5 to 15 μM.
[0029] If the pluripotent stem cells are ES cells, then the culture medium may also contain nucleases that function as aggregation inhibitors (e.g., DNase) and insulin-like growth factor (IGF) (e.g., IGF1) that function as insulin-like growth factor (IGF) receptor agonists.
[0030] If the pluripotent stem cells are iPS cells, it is advisable to first replace the culture medium with one containing glucose, FAF-BSA, ITS system supplements (e.g., ITS-X), NaHCO3, L-glutamine (L-Glu), etc., to initiate differentiation, and then add the above-mentioned culture medium components (i.e., activin receptor-like kinase-4,7 activators (e.g., Activin-A), GSK3 inhibitors (e.g., CHIR99021), and Rock inhibitors (e.g., Y27632)). Furthermore, ITS system supplements (e.g., ITS-X), NaHCO3, L-glutamine (L-Glu), antibiotics (e.g., penicillin-streptomycin (PS)), etc. may be added.
[0031] Examples of basal culture media include StemFit AK (IGF) medium, MCDB 131 medium, Dulbecco's Modified Eagle Medium (DMEM) medium, Glasgow's MEM (GMEM) medium, RPMI 1640 medium, Iscove's Modified DMEM (IMDM) medium, Medium 199 (M199) medium, Williams' Medium E medium, Human Plasma-Like Medium (HPLM) medium, and mixtures thereof. If the pluripotent stem cells are ES cells, the medium may be zinc-free.
[0032] Cell culture in this stage is carried out by culturing the cells in a CO2 incubator at a culture temperature suitable for the stem cells being used (usually 30-40°C, preferably around 37°C). The culture period is 1 to 10 days, preferably 1 to 3 days.
[0033] The differentiation of stem cells into endodermal cells can be confirmed by evaluating changes in the expression of proteins and genes (hereinafter sometimes referred to as endodermal markers) that are specifically expressed in endodermal cells. Evaluation of these endodermal marker expression changes can be performed, for example, by methods such as protein expression evaluation using antigen-antibody reactions or gene expression evaluation using quantitative RT-PCR. Examples of endodermal markers include SOX17 and FOXA2.
[0034] Stage 2 (Gastrotrutic Transition): Endoderm cells of the embryo are induced to differentiate into gastrulatic cells (primitive gut tubes).
[0035] On days 3 and 5 (the number of days since the start of pluripotent stem cell culture), the culture medium is replaced with a medium containing an FGFR2b agonist (e.g., KGF).
[0036] The concentration of the FGFR2b agonist (e.g., KGF) in the culture medium is preferably 1 to 300 ng / mL, more preferably 5 to 200 ng / mL, and more preferably 20 to 100 ng / mL.
[0037] The culture medium may also be supplemented with glucose, FAF-BSA, ITS-based supplements (e.g., ITS-X), NaHCO3, L-glutamine (L-Glu), antibiotics (e.g., penicillin-streptomycin (PS)), vitamins (e.g., vitamin C), etc.
[0038] Examples of basal media include MCDB 131 medium, Dulbecco's Modified Eagle Medium (DMEM), Glasgow's MEM (GMEM), RPMI 1640 medium, Iscove's Modified DMEM (IMDM), Medium 199 (M199), Williams' Medium E medium, Human Plasma-Like Medium (HPLM), and mixtures thereof.
[0039] Cell culture in this stage is carried out by culturing the endodermal cells used in a CO2 incubator at a culture temperature suitable for culturing (usually 30-40°C, preferably around 37°C). The culture period is 1 to 7 days, preferably 1 to 3 days.
[0040] The differentiation of endodermal cells into gastrula cells can be confirmed by evaluating changes in the expression of proteins and genes specifically expressed in gastrula cells (hereinafter sometimes referred to as gastrula cell markers) using methods such as protein expression evaluation using antigen-antibody reactions or gene expression evaluation using quantitative RT-PCR. Examples of these cell markers include FOXA2, HNF1b, and HNF4a.
[0041] Stage 3 (foregut posterior cell differentiation): Gastrunitic cells are induced to differentiate into foregut posterior cells.
[0042] On day 6 (number of days since the start of pluripotent stem cell culture), the culture medium is replaced with a medium containing an FGFR2b agonist (e.g., KGF), a protein kinase C activator (e.g., PdBU:phorbol 12,13-dibutyrate), a retinoic acid receptor (RAR) agonist (e.g., RA), a Hedgehog signaling inhibitor (e.g., SANT-1), a BMP signaling inhibitor (e.g., LDN193189), and a Rock inhibitor (e.g., Y27632).
[0043] The concentration of the FGFR2b agonist (e.g., KGF) in the culture medium is preferably 1 to 300 ng / mL, more preferably 5 to 200 ng / mL, and more preferably 20 to 100 ng / mL.
[0044] The concentration of the protein kinase C activator (e.g., PdBU) in the culture medium is preferably 1 to 5000 nM, more preferably 10 to 2000 nM, and more preferably 200 to 1000 nM.
[0045] The concentration of the retinoic acid receptor (RAR) agonist (e.g., RA) in the culture medium is preferably 0.01 to 10 μM, more preferably 0.05 to 5 μM, and more preferably 1 to 3 μM.
[0046] The concentration of the hedgehog signaling inhibitor (e.g., SANT-1) in the culture medium is preferably 0.01 to 5 μM, more preferably 0.05 to 1 μM, and more preferably 0.1 to 0.5 μM.
[0047] The concentration of the BMP signaling inhibitor (e.g., LDN193189) in the culture medium is preferably 1 to 2000 nM, more preferably 10 to 1000 nM, and more preferably 50 to 400 nM.
[0048] The concentration of the Rock inhibitor (e.g., Y27632) in the culture medium is preferably 0.1 to 100 μM, more preferably 0.5 to 30 μM, and more preferably 5 to 15 μM.
[0049] The culture medium may also be supplemented with glucose, FAF-BSA, ITS-based supplements (e.g., ITS-X), NaHCO3, L-glutamine (L-Glu), vitamins (e.g., vitamin C), etc.
[0050] Examples of basal media include MCDB 131 medium, Dulbecco's Modified Eagle Medium (DMEM) medium, DMEM / F12 medium, F12 medium, Glasgow's MEM (GMEM) medium, RPMI 1640 medium, Iscove's Modified DMEM (IMDM) medium, Medium 199 (M199) medium, Williams' Medium E medium, Human Plasma-Like Medium (HPLM) medium, and mixtures thereof.
[0051] Cell culture in this stage is carried out by culturing the gastrulline cells used in a CO2 incubator at a culture temperature suitable for culturing (usually 30-40°C, preferably around 37°C). The culture period is 1 to 5 days, preferably around 1 day.
[0052] At this stage, confirmation of the differentiation of gastrulatal cells into posterior foregut cells can be achieved by evaluating changes in the expression of proteins and genes specifically expressed in posterior foregut cells (hereinafter sometimes referred to as posterior foregut cell markers) using methods such as protein expression evaluation using antigen-antibody reactions or gene expression evaluation using quantitative RT-PCR. Examples of these cell markers include FOXA2, PDX1, and SOX9.
[0053] Stage 4 (Pancreatic progenitor cell differentiation): Posterior foregut cells are induced to differentiate into pancreatic progenitor cells.
[0054] From day 7 to day 11 (number of days from the start of pluripotent stem cell culture), the stem cells are cultured in a medium containing an FGFR2b agonist (e.g., KGF), a retinoic acid receptor (RAR) agonist (e.g., RA), a Hedgehog signaling inhibitor (e.g., SANT-1), an activin receptor-like kinase-4,7 activator (e.g., Activin-A), and a Rock inhibitor (e.g., Y27632).
[0055] The concentration of the FGFR2b agonist (e.g., KGF) in the culture medium is preferably 1 to 300 ng / mL, more preferably 5 to 200 ng / mL, and more preferably 20 to 100 ng / mL.
[0056] The concentration of the hedgehog signaling inhibitor (e.g., SANT-1) in the culture medium is preferably 0.01 to 5 μM, more preferably 0.05 to 1 μM, and more preferably 0.1 to 0.5 μM.
[0057] The concentration of the retinoic acid receptor (RAR) agonist (e.g., RA) in the culture medium is preferably 1 to 500 nM, more preferably 5 to 400 nM, and more preferably 50 to 200 nM.
[0058] The concentration of the activator of activin receptor-like kinase-4,7 (e.g., Activin-A) in the culture medium is preferably 0.05 to 50 ng / mL, more preferably 0.1 to 20 ng / mL, and more preferably 2 to 10 ng / mL.
[0059] The concentration of the Rock inhibitor (e.g., Y27632) in the culture medium is preferably 0.1 to 100 μM, more preferably 0.5 to 30 μM, and more preferably 5 to 15 μM.
[0060] The culture medium may also be supplemented with glucose, FAF-BSA, ITS-based supplements (e.g., ITS-X), NaHCO3, L-glutamine (L-Glu), vitamins (e.g., vitamin C), etc.
[0061] Examples of basal media include MCDB 131 medium, Dulbecco's Modified Eagle Medium (DMEM) medium, DMEM / F12 medium, F12 medium, Glasgow's MEM (GMEM) medium, RPMI 1640 medium, Iscove's Modified DMEM (IMDM) medium, Medium 199 (M199) medium, Williams' Medium E medium, Human Plasma-Like Medium (HPLM) medium, and mixtures thereof.
[0062] Cell culture in this stage is carried out by culturing the posterior foregut cells used in a CO2 incubator at a culture temperature suitable for culturing (usually 30-40°C, preferably around 37°C). The culture period is 1 to 10 days, preferably 1 to 5 days.
[0063] At this stage, confirmation of differentiation induction of posterior foregut cells into pancreatic progenitor cells can be achieved by evaluating changes in the expression of proteins and genes specifically expressed by pancreatic progenitor cells (hereinafter sometimes referred to as pancreatic progenitor cell markers) using methods such as protein expression evaluation using antigen-antibody reactions or gene expression evaluation using quantitative RT-PCR. Examples of these cell markers include PDX1, HNF6, and SOX9.
[0064] Stage 5 (Endocrine Induction): Pancreatic progenitor cells are induced to differentiate into endocrine progenitor cells, and further differentiated into immature β-cells.
[0065] From day 12 to day 15 (number of days from the start of pluripotent stem cell culture), the stem cells are cultured in a medium containing a TGF-βI activin receptor-like kinase-4,5,7 inhibitor (e.g., ALK5i), a retinoic acid receptor (RAR) agonist (e.g., RA), a Hedgehog signaling inhibitor (e.g., SANT-1), a γ-secretase inhibitor (e.g., XXI), an EGF family growth factor (e.g., Betacellulin), the thyroid hormone GC1 / T3, and heparin. From day 16 to day 19, the stem cells are cultured in the same medium without the Hedgehog signaling inhibitor (e.g., SANT-1). The concentration of the retinoic acid receptor (RAR) agonist (e.g., RA) may be reduced.
[0066] The concentration of TGF-βI activin receptor-like kinase-4,5,7 inhibitors (e.g., ALK5i) in the culture medium is preferably 0.1 to 100 μM, more preferably 0.5 to 30 μM, and more preferably 5 to 15 μM.
[0067] The concentration of the hedgehog signaling inhibitor (e.g., SANT-1) in the culture medium is preferably 0.01 to 5 μM, more preferably 0.05 to 1 μM, and more preferably 0.1 to 0.5 μM.
[0068] The concentration of the retinoic acid receptor (RAR) agonist (e.g., RA) in the culture medium is preferably 1 to 500 nM, more preferably 5 to 400 nM, and more preferably 50 to 200 nM.
[0069] The concentration of the γ-secretase inhibitor (e.g., XXI) in the culture medium is preferably 0.01 to 10 μM, more preferably 0.05 to 5 μM, and more preferably 0.5 to 2 μM.
[0070] The concentration of EGF family growth factors (e.g., betacellulin) in the culture medium is preferably 0.1 to 200 ng / mL, more preferably 1 to 100 ng / mL, and more preferably 10 to 30 ng / mL.
[0071] The concentration of thyroid hormone GC1 / T3 in the culture medium is preferably 0.01 to 10 μM, more preferably 0.05 to 5 μM, and more preferably 0.5 to 2 μM.
[0072] The concentration of heparin in the culture medium is preferably 0.1 to 100 ng / mL, more preferably 0.5 to 30 ng / mL, and more preferably 5 to 15 ng / mL.
[0073] The culture medium may also be supplemented with glucose, FAF-BSA, ITS-based supplements (e.g., ITS-X), NaHCO3, L-glutamine (L-Glu), antibiotics (e.g., penicillin-streptomycin (PS)), vitamins (e.g., vitamin C), etc.
[0074] Examples of basal media include MCDB 131 medium, Dulbecco's Modified Eagle Medium (DMEM) medium, DMEM / F12 medium, F12 medium, Glasgow's MEM (GMEM) medium, RPMI 1640 medium, Iscove's Modified DMEM (IMDM) medium, Medium 199 (M199) medium, Williams' Medium E medium, Human Plasma-Like Medium (HPLM) medium, and mixtures thereof.
[0075] Cell culture in this stage is carried out by culturing the pancreatic progenitor cells used in a CO2 incubator at a culture temperature suitable for the cells (usually 30-40°C, preferably around 37°C). The culture period is 1 to 15 days, preferably 1 to 8 days.
[0076] At this stage, confirmation of the differentiation of pancreatic progenitor cells into endocrine progenitor cells can be achieved by evaluating changes in the expression of proteins and genes specifically expressed by endocrine progenitor cells (hereinafter sometimes referred to as endocrine progenitor cell markers) using methods such as protein expression evaluation using antigen-antibody reactions or gene expression evaluation using quantitative RT-PCR. Examples of these cell markers include NGN3, PAX4, NKX6.1, and NEUROD1.
[0077] At this stage, confirmation of the differentiation of endocrine progenitor cells into immature β-cells can be achieved by evaluating changes in the expression of proteins and genes specifically expressed in immature β-cells (hereinafter sometimes referred to as immature β-cell markers) using methods such as protein expression evaluation using antigen-antibody reactions or gene expression evaluation using quantitative RT-PCR. Examples of these cell markers include insulin, C-peptide, and NKX6.1.
[0078] Stage 6 (Endocrine system maturation): Immature β-cells differentiate into mature β-cells.
[0079] From day 20 to day 31 (number of days from the start of pluripotent stem cell culture), the cells are cultured in a medium containing Zn, trace element A, trace element B, and heparin.
[0080] The concentration of Zn (e.g., ZnSO4) in the culture medium is preferably 0.1 to 100 μM, more preferably 0.5 to 30 μM, and more preferably 5 to 15 μM.
[0081] The concentration of trace element A in the culture medium is preferably 0.001 to 1%, more preferably 0.01 to 0.5%, and more preferably 0.05 to 0.2%.
[0082] The concentration of trace element B in the culture medium is preferably 0.001 to 1%, more preferably 0.01 to 0.5%, and more preferably 0.05 to 0.2%.
[0083] The concentration of heparin in the culture medium is preferably 0.1 to 100 ng / mL, more preferably 0.5 to 30 ng / mL, and more preferably 5 to 15 ng / mL.
[0084] The culture medium may also contain glucose, FAF-BSA, NaHCO3, L-glutamine (L-Glu), antibiotics (e.g., penicillin-streptomycin (PS)), non-essential amino acids (NEAAs) (specifically, 10 mM L-alanine, 10 mM L-asparagine monohydrate (L-Asparagine·H2O), 10 mM L-aspartic acid, 10 mM L-glutamic acid, 10 mM glycine, 10 mM L-proline, and 10 mM L-serine).
[0085] Examples of basal culture media include MCDB 131 medium.
[0086] Cell culture in this stage is carried out by culturing the immature β cells used in a CO2 incubator at a culture temperature suitable for culturing (usually 30-40°C, preferably around 37°C). The culture period is 1 to 16 days, preferably 1 to 8 days.
[0087] At this stage, confirmation of the differentiation of immature β-cells into mature β-cells can be achieved by evaluating changes in the expression of proteins and genes specifically expressed in mature β-cells (hereinafter sometimes referred to as mature β-cell markers) using methods such as protein expression evaluation using antigen-antibody reactions or gene expression evaluation using quantitative RT-PCR. Examples of these cell markers include insulin, C-peptide, and NKX6.1.
[0088] Specific examples of components to be added to the culture medium used in any of the above stages 1-6 are described below.
[0089] Examples of activators for activin receptor-like kinases-4 and 7 include activin, Nodal, and Myostatin, with activin being preferred. While activins A, B, C, D, and AB are known, any of these can be used, with activin A being preferred. Activins derived from any mammal, such as humans or mice, can be used, but it is preferable to use activins derived from the same animal species as the stem cells used for differentiation. For example, when using human stem cells as a starting material, it is preferable to use human-derived activin, particularly human-derived activin A. These activins are commercially available.
[0090] Examples of GSK3 inhibitors include CHIR98014, CHIR99021, Kenpaullone, AR-AO144-18, TDZD-8, SB216763, BIO, TWS-119, and SB415286. These are commercially available. Even if they are not commercially available, those skilled in the art can prepare them according to known literature. Antisense oligonucleotides and siRNAs against GSK3 mRNA can also be used as GSK3 inhibitors. These are all commercially available or can be synthesized according to known literature. The GSK3 inhibitor is preferably selected from the group consisting of CHIR99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazole-2-yl)-2-pyrimidinyl]amino]ethyl]amino]nicotinonitrile), SB216763 (3-(2,3-dichlorophenyl)-4-(1-methyl-1H-indole-3-yl)-1H-pyrrole-2,5-dione), and SB415286 (3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione), with CHIR99021 being particularly preferred. CHIR99021 is a substance that activates the Wnt signaling pathway.
[0091] Examples of Rock inhibitors include Y27632, H1152, Y-39983, and Thiazovivin. These are available commercially. The Rock inhibitor is preferably Y27632.
[0092] Examples of FGFR2b agonists include KGF, FGF10, and the KGF substitute peptide PG-012. These are commercially available. KGF is preferred as the FGFR2b agonist.
[0093] Examples of protein kinase C activators include PdBU (phorbol 12,13-dibutyrate), 12-O-tetradecanoylphorbol-13-(4-nitrobenzoate) (TTNTB), and phorbol 12-myristate-13-acetate (PMA; TPA). These are commercially available. PdBU is preferred as the protein kinase C activator.
[0094] Retinoic acid receptor (RAR) agonists may be naturally occurring retinoids, chemically synthesized retinoids, retinoic acid receptor agonist compounds lacking a retinoid skeleton, or natural products possessing retinoic acid receptor agonist activity. An example of a natural retinoid with RAR agonist activity is retinoic acid (including its isomers). Examples of retinoic acid, though not limited to these, include the all-trans isomer (tretinone) and 9-cis-retinoic acid (9-cisRA). Chemically synthesized retinoids are also well known in the art. Examples of retinoic acid receptor agonist compounds lacking a retinoid skeleton include Am80, AM580, TTNPB, and AC55649. Examples of natural products possessing retinoic acid receptor agonist activity include honokiol and magnolol. The RAR agonist is preferably retinoic acid, AM580 (4-[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carboxamide]benzoic acid), TTNPB (4-[[E]-2-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]-1-propenyl]benzoic acid), AC55649 (4'-octyl-[1,1'-biphenyl]-4-carboxylic acid), and more preferably retinoic acid.
[0095] Hedgehog signaling inhibitors are not particularly limited as long as they are substances that have inhibitory activity on hedgehog signaling, and may be naturally occurring substances or chemically synthesized substances. Preferred examples of hedgehog signaling inhibitors include cyclopamine, KAAD-cyclopamine (28-[2-[[6-[(3-phenylpropanoyl)amino]hexanoyl]amino]ethyl]-17β,23β-epoxyveratraman-3-one), analogs of KAAD-cyclopamine, gelvin (17,23β-epoxy-3β-hydroxyveratraman-11-one), analogs of gelvin, SANT-1, hedgehog pathway blocking antibodies, etc., with SANT-1 being particularly preferred.
[0096] BMP signaling inhibitors are compounds that have inhibitory activity over BMP signaling, which occurs through the binding of BMP to BMP receptors (type I or type II). These inhibitors include both protein-based and small-molecule inhibitors. Examples of protein-based inhibitors include natural inhibitors such as noggin, chordin, follistatin, cerberus, and gremlin. Noggin is known to inhibit BMP signaling by inhibiting the binding of BMP4 to the BMP receptor. Examples of small-molecule inhibitors include compounds that inhibit BMP2, BMP4, BMP6, or BMP7, which have the ability to activate transcription factors SMAD1, SMAD5, or SMAD8. Examples include dorsomorphin (6-[4-(2-piperidine-1-ylethoxy)phenyl]-3-pyridine-4-ylpyrazolo[1,5-a]pyrimidine) and its derivatives. Other BMPI receptor kinase inhibitors include LDN-193189 (4-(6-(4-piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyridine-3-yl)quinoline) and its derivatives. These compounds are commercially available, but if they are not commercially available, they can be prepared according to known literature. LDN-193189 is preferred as the BMPI receptor kinase inhibitor.
[0097] Examples of TGF-βI activin receptor-like kinase-4,5,7 inhibitors include ALK5i II, RepSox (E-616452), SB-431542, and A-83-01. These are available commercially.
[0098] Examples of γ-secretase inhibitors include XXI, N-[(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), 4-[2,2-dimethyl-1-(4-(2-methylpropylaminomethyl)phenyl)propyl]phenyl γ-butyrate (LY-411575), dibenzazepine (DBZ), BMS-708163, RO4929097, etc. These are available commercially. The γ-secretase inhibitor is preferably XXI.
[0099] Examples of EGF family growth factors include betacellulin, which is available commercially.
[0100] Examples of thyroid hormones include natural hormones such as T4, Triac, DITPA, and T2, as well as synthetic analogs such as GC-1 (sobetirome), GC-24, KB-141, KB-2115 (eprotirome), MGL-3196 (resmetirome), and VK2809, which are TRβ-selective agonists. These are available commercially. The thyroid hormone is preferably GC1 / T3.
[0101] Aggregation inhibitors are often "nucleases," which include enzymes that hydrolyze phosphodiester bonds in DNA. Nucleases include, but are not limited to, DNase I, DNase II, and their functional equivalents (derivatives, fusion proteins, PEG-modified products, etc.). In this invention, "DNase I" specifically refers to a nuclease capable of specifically degrading DNA, whether mammalian or microbial, and used with a final activity of approximately 0.5 μg / mL to 20 μg / mL, preferably 1 μg / mL to 5 μg / mL, under culture conditions.
[0102] Examples of insulin-like growth factor (IGF) receptor agonists include IGF-1, IGF-2, and their functional equivalents (derivatives, mutants, etc.).
[0103] ITS supplements refer to mixtures containing insulin or its functional equivalents (IGF-1, IGF-2, etc.), transferrin or iron donors, and selenium compounds, and may optionally contain ethanolamine, linoleic acid, pyruvate, vitamins, and other culture-promoting ingredients. This includes commercially available products such as ITS-X, ITS-A, and ITS Premix, as well as their recombinant or custom formulations.
[0104] The above six-stage pancreatic differentiation protocol may be replaced with the differentiation protocols listed in the table below. The culture duration and additives in the table may be changed as appropriate. Butyrate should be added to the culture medium at stage 6 of the differentiation protocol by Hogrebe 2021, stage 7 of the differentiation protocol by Liang 2023, stage 6 of the differentiation protocol by Pollock 20241, stage 6 of the differentiation protocol by Verhoeff 20251, stage 7 of the differentiation protocol by Barsby 2022, and stage 6 of the differentiation protocol by Velazco-Cruz 2019. JPEG2026182235000002.jpg244160
[0105] The present invention also allows for the production of insulin-producing β-cells from mesenchymal stem cells or pancreatic progenitor cells produced by direct reprogramming. Methods for differentiating mesenchymal stem cells into insulin-producing β-cells are described in literature such as Nour Eldeen et at Sci Rep. (2024) 14:24417, and methods for producing insulin-producing β-cells from pancreatic progenitor cells produced by direct reprogramming are described in literature such as Fontcuberta-PiSunyer et al Commun Biol (2023) 6:256. Insulin-producing β-cells can also be produced by adding butyrate to the culture medium during the later stages of culture in the methods described in these literature to mature the β-cells.
[0106] The method of the present invention allows for the efficient differentiation of stem cells into insulin-producing β-cells, thereby enabling the supply of large quantities of cells that specifically produce insulin (cells that secrete insulin secretagogues and C-peptides in response to hyperglycemia, and which have significantly superior insulin expression capacity compared to other pancreatic hormones). These insulin-producing β-cells can be used as a tool for developing pharmaceuticals (particularly pharmaceuticals for cell therapy) and diabetes treatments.
[0107] The present invention provides insulin-producing β-cells that can be prepared by the above method and can secrete C-peptide at a rate of 0.1 pg / min / 1000 cells or more under conditions where the glucose concentration is 20 mM. The insulin-producing β-cells of the present invention often secrete C-peptide at a rate of 0.2 pg / min / 1000 cells or more, 0.3 pg / min / 1000 cells or more, 0.4 pg / min / 1000 cells or more, 0.5 pg / min / 1000 cells or more, and 1.0 pg / min / 1000 cells or more under conditions where the glucose concentration is 20 mM, and preferably at a rate of 1.0 pg / min / 1000 cells or more. The amount of C-peptide secreted can be measured by the C-peptide release assay described in the examples below.
[0108] The insulin-producing β cells of the present invention can be utilized as a cell medicine. The insulin-producing β cells of the present invention are formulated into a preparation and administered to human or animal patients as a pharmaceutical product (pharmaceutical composition). The pharmaceutical composition containing the insulin-producing β cells of the present invention enables insulin production (secretion) in the patient's body by its own administration (transplantation), and is useful for the treatment of diabetes, a disease caused by decreased insulin production (secretion). Examples of the dosage form include suspensions, capsules, cell sheets and the like. The additive may be appropriately selected and used from additives approved for pharmaceutical products.
[0109] Examples of the administration form (transplantation method) of the pharmaceutical composition containing the insulin-producing β cells of the present invention to humans include a method of making a small incision in the right lower abdomen of a human patient, exposing the thin blood vessels of the mesentery, and inserting a catheter under direct visualization to transplant the cells; a method of identifying the hepatic portal vein by ultrasound and puncturing the catheter to transplant the cells; or a method of transplanting into the spleen by directly puncturing the spleen under abdominal ultrasound guidance (see Nagata H, Ito M, Shirota C, Edge A, McCowan TC, Fox IJ: Route of hepatocyte delivery affects hepatocyte engraftment in the spleen. Transplantation, 76(4):732-4, 2003). Among these, the method of performing cell transplantation using ultrasound is preferred because it is less invasive, and a specific example of such a method includes a method of transplanting into the spleen or liver by direct puncture under abdominal ultrasound guidance. The dose (transplantation amount) of the pharmaceutical composition containing the insulin-producing β cells of the present invention is, for example, 1×10 8 ~1×10 10 cells / individual, preferably 5×10 8 ~1×10 10 cells / individual, more preferably 1×10 9 ~1×10 10It is a cell / individual. In the pharmaceutical composition containing insulin-producing β cells of the present invention, it is preferable to use insulin-producing β cells created using the patient's own cells or cells from a donor whose tissue compatibility is within an acceptable range, and in particular, insulin-producing β cells differentiated (manufactured) in a xenofree culture system. Furthermore, the dosage (transplant amount) of the pharmaceutical composition containing insulin-producing β cells of the present invention can be appropriately changed depending on the age, weight, symptoms, etc. of the patient to whom it is administered.
[0110] The insulin-producing β-cells of the present invention can be used in a screening method for diabetes treatment drugs, and the screening method can be carried out, for example, as follows: Using the insulin-producing β-cells of the present invention, the amount of insulin expressed in the cells or the amount of insulin secreted outside the cells is measured and compared in two cases: (a) when the insulin-producing β-cells are cultured in the presence of a test compound, and (b) when the insulin-producing β-cells are cultured in the absence of the test compound.
[0111] Insulin expression levels include the amount of insulin expressed and the amount of polynucleotides (e.g., mRNA) that encode insulin. The amount of insulin expressed and secreted can be measured by known methods, such as using an antibody that recognizes insulin, to measure the amount of insulin present in cell extracts or culture media by methods such as Western blotting analysis or ELISA, or similar methods.
[0112] The amount of insulin mRNA can be measured according to known methods, such as Northern hybridization, S1 mapping, PCR, quantitative RT-PCR, DNA chip or array methods, or similar methods.
[0113] The culture of insulin-producing β-cells can be carried out according to known methods, without particular limitations, as long as conditions are met under which insulin is expressed and / or secreted. Suitable culture media include, for example, MEM medium, DMEM medium, RPMI 1640 medium, or 199 medium, each containing approximately 1-20% fetal bovine serum.
[0114] There are no particular restrictions on the test compounds, and examples include synthetic compounds, natural compounds, low molecular weight compounds, peptides, proteins, and extracts derived from plants, animals, or living organisms.
[0115] The present invention's screening method using insulin-producing β-cells can detect both substances that suppress (inhibit) insulin production and substances that promote it. Substances that promote insulin production, as screened in this way, are useful as therapeutic agents for diabetes.
[0116] Furthermore, the present invention also provides a culture medium for maturing immature β cells into insulin-producing β cells, the culture medium containing butyric acid.
[0117] The culture medium of the present invention is suitable for use in stage 6 of the pancreatic differentiation protocol described above. The medium preferably contains Zn, trace element A, trace element B, and heparin, and may also contain glucose, FAF-BSA, NaHCO3, L-glutamine (L-Glu), antibiotics (e.g., penicillin-streptomycin (PS)), non-essential amino acids (NEAA), etc. The basal medium may also contain components of other media such as MCDB 131 medium, Dulbecco's Modified Eagle Medium (DMEM) medium, DMEM / F12 medium, F12 medium, Glasgow's MEM (GMEM) medium, RPMI 1640 medium, Iscove's Modified DMEM (IMDM) medium, Medium 199 (M199) medium, Williams' Medium E medium, and Human Plasma-Like Medium (HPLM) medium. [Examples]
[0118] The present invention will be described in more detail below with reference to examples. [Example 1] Abstract Transplantation of stem cell-derived β-cells (SC-β) presents a promising approach to diabetes treatment, relying on high differentiation efficiency and robust functional maturation. Our previous research showed that pre-differentiation methionine depletion and zinc deficiency during early differentiation enhanced pancreatic differentiation efficiency (Cell Reports, 2022; Star Protocols, 2023). Based on these findings, we developed an improved protocol combining methionine depletion with supplementation of short-chain fatty acids (SCFAs), metabolites of the gut microbiota, to further enhance glucose-stimulated insulin secretion (GSIS) in SC-β cells. In this study, we evaluated the effects of SCFAs, particularly acetate, propionic acid, and butyrate, on SC-β differentiation at key stages, including endodermal formation (stage 1), pancreatic progenitor cell differentiation (stage 4), and endocrine system maturation (stage 6). We found that butyrate supplementation at stage 1 inhibited endodermal differentiation and induced cell death. Furthermore, when butyrate was added at stage 4, cells differentiated into β cells, but GSIS ability was lost. Notably, when butyrate supplementation was added at stage 6, GSIS was significantly enhanced. In contrast, acetate and propionic acid did not show any beneficial effect on GSIS at stage 6. Gene expression analysis revealed that butyrate addition at stage 6 reduced insulin gene expression. These findings highlight the synergistic potential of methionine depletion and SCFA supplementation in promoting the functional maturation of SC-β cells, providing a solid foundation for advancing stem cell-based therapies for diabetes.
[0119] result To investigate the effect of SCFA on β-cell differentiation, a six-stage differentiation procedure from Stage 1 to Stage 6 was performed using a three-dimensional rotating culture system to generate insulin-expressing pancreatic β-cells from human ESCs. Butyrate, propionic acid, and acetate were administered at a concentration of 1 mM each during Stage 1 (days 0-3), Stage 4 (days 7-12), and Stage 6 (days 20-31) (Figure 1A). The effect of SCFA administration in Stage 1 on endodermal differentiation was evaluated on day 3 by morphological analysis and immunocytochemistry (Figure 1B). The butyrate-treated group showed a significant decrease in cell number compared to the control group, and a decrease in SOX17-positive OCT3 / 4-negative endodermal cells was observed even in the remaining cells. Furthermore, the effect of SCFA treatment on the differentiation of pancreatic progenitor cells in Stages 1 and 4 was evaluated immunocytochemistry on day 12, as depicted in Figure 1C. Administration of propionic acid in Stage 1 reduced the proportion of PDX1+ / NKX6.1+ cells and significantly inhibited the differentiation of endocrine progenitor cells. On the other hand, while butyrate treatment drastically reduced cell numbers when added in Stage 1, it did not induce cell death when added in Stage 4, but similar to propionic acid treatment, it reduced the proportion of PDX1+ / NKX6.1+ cells and significantly inhibited the differentiation of progenitor cells. Finally, the effects of SCFAs treatment in Stages 1, 4, and 6 on the differentiation of mature pancreatic β-cells were compared by immunocytochemistry on day 31 (Figure 1D). Addition of butyrate in Stage 6 increased the proportion of C-peptide and NKX6.1-positive pancreatic β-cells.
[0120] In summary, we evaluated the effects of SCFAs on the differentiation of hESCs into pancreatic β-cells. Stage 1 butyrate induced significant cell death and inhibited endodermal differentiation. Both stage 1 propionic acid and stage 4 butyrate reduced the differentiation of pancreatic progenitor cells. Conversely, stage 6 butyrate promoted the formation of mature β-cells. These results indicate that SCFAs exert various effects at different stages of pancreatic differentiation. Notably, butyrate, which acts as a differentiation promoter in the two-dimensional endodermal differentiation system, was found to induce significant cell death in the three-dimensional rotational differentiation system, making it unsuitable for differentiation purposes.
[0121] Next, the effect of SCFA on stage 6 of the pancreatic differentiation system was evaluated in 3D rotational culture using human iPS cells (RPChiPS7713G1). An established method of promoting differentiation by removing methionine was adopted (Sim et al., 2022). As shown in Figure 2B, when butyrate was added from D20, sphere aggregation occurred and the diameter increased. On the other hand, this aggregation formation was suppressed by changing the timing of butyrate addition from D22 to D31. Furthermore, immunohistochemical staining results showed that the addition of butyrate from D22 reduced the number of pancreatic β cells that were positive for both C-peptide and Nkx6.1 (Figure 2C). Furthermore, when glucose-stimulated insulin secretion was evaluated, it was shown that the addition of butyrate tended to increase C-peptide secretion under low glucose conditions (3 mM). Furthermore, as shown in Figure 2D, a significant increase in C-peptide secretion was observed under high glucose concentration conditions (20 mM). Furthermore, quantitative PCR revealed a significant decrease in insulin mRNA in the butyrate-administered group (Figure 2E). Next, to further investigate the effective concentration, the effects of adding 0.1 mM and 1 mM butyrate on insulin secretion were evaluated using stage 5 hiPSC-derived pancreatic β-cells. The results showed that adding 1 mM butyrate promoted insulin secretion in both the low-glucose and high-glucose groups (Figure 2F).
[0122] In conclusion, using continuous three-dimensional rotational differentiation throughout all differentiation stages, butyrate administration at stage 6 was observed to significantly enhance GSIS despite decreasing insulin mRNA levels. These findings suggest that butyrate promotes substantial functional maturation of pancreatic β-cells independently of insulin gene expression.
[0123] Subsequently, the reproducibility of the GSIS-enhancing effect of butyrate treatment in stage S6 was verified, and the effect of SCFA addition in stage S4 was re-evaluated (Figure 3A). When C-peptide secretion was examined, no effect related to SCFA treatment was observed in stage 4, but conversely, it was observed that C-peptide secretion was consistently promoted when butyrate was added in stage 6 (Figure 3B). The supplementation effect of butyrate in stage 6 showed a robust and reproducible promotion of C-peptide secretion, particularly highlighting the usefulness of butyrate in promoting the functional maturation of pancreatic cells in the later stages of differentiation. On the other hand, SCFA administration in the early stages (stages 1 and 4) did not produce any beneficial effects in this pancreatic differentiation.
[0124] discussion This study investigated the stage-specific effects of SCFAs, particularly butyrate, on pancreatic β-cell differentiation from hPSCs in a three-dimensional rotating culture system. The results revealed previously unrecognized complexities. In particular, the effects of SCFAs differed significantly depending on the differentiation stage and culture dimension. Administration of butyrate during the endodermal differentiation stage induced significant cell death and impaired differentiation in the three-dimensional rotating culture method (Figure 1B). Conversely, administration of butyrate in the later stages significantly promoted functional maturation (Figures 2DF and 3B), as indicated by increased GSIS despite decreased insulin mRNA expression (Figure 2E). This suggests that the differentiation-promoting ability of butyrate is context-dependent, emphasizing the need for careful consideration of precise timing and culture conditions when using SCFAs to promote pancreatic β-cell differentiation in vitro.
[0125] Traditionally, butyrate administration has been typically performed during the early stages of differentiation into hepatocyte or pancreatic cell lines. In the case of early differentiation, 1 mM butyrate promotes Activin-mediated embryonic endoderm differentiation from human ESCs, ultimately leading to pancreatic differentiation (Jiang et al., 2007). Regarding pancreatic differentiation, one study showed that treatment with 1 mM butyrate during the early differentiation of mouse ESCs significantly promoted differentiation into exocrine pancreatic cells (Ren et al., 2009). Furthermore, another report highlighted that the combined use of dimethyl sulfoxide (DMSO), 2.5 mM butyrate, and hepatocyte growth factor (HGF) achieved efficient conversion of mouse ESCs into hepatic progenitor cells. Of these factors, butyrate treatment significantly promoted the induction of hepatic progenitor cells (Zhou et al., 2007). In addition, there are conflicting reports regarding the effects of SCFA on mature pancreatic islets, emphasizing the need for further investigation. For example, Oergaard et al. showed that while acetic acid, propionic acid, and butyrate did not affect glucagon secretion in isolated mouse pancreatic islets, all three SCFAs exerted mild inhibitory effects on somatostatin and insulin secretion. In particular, 10 mM butyrate significantly suppressed insulin secretion under high glucose conditions (Wang et al., 2022). In contrast, Wang et al. reported that long-term incubation with 5 mM butyrate promoted insulin secretion from rat pancreatic islets within a range of glucose concentrations (3.3, 8.3, 16.7 mM) without altering insulin content or cytotoxicity (Wang et al., 2022). These differences are thought to be due to differences in SCFA concentration (10 mM vs. 5 mM), animal species (mouse vs. rat), and exposure duration (acute vs. chronic). Therefore, comprehensive studies using human pancreatic islets and detailed dose-response analyses are needed to clarify the precise effects of SCFAs on mature pancreatic β-cells.
[0126] As mentioned above, butyrate has long been studied for its differentiation-promoting effect in endodermal differentiation, the first stage of pancreatic differentiation. However, it is not included in the current standard 3D rotational differentiation system for pancreatic differentiation of PSCs, such as the one developed by Pagliuca et al. in 2014 (Pagliuca et al., 2014). One possible reason for the omission of butyrate from the standard method is concern about excessive inhibition of cell proliferation due to butyrate addition. In fact, when butyrate was administered during the early differentiation stage of 3D rotational culture, significant cell death was observed, and further culture and differentiation were hindered (Figure 1B). One possible explanation for this cytotoxicity is the intracellular accumulation of butyrate. In addition, the involvement of the Warburg effect (Abdel-Haleem et al., 2017), which is commonly observed in highly proliferating cells such as cancer cells and undifferentiated PSCs, is also possible. This metabolic preference may lead to increased accumulation of butyrate, resulting in pronounced histone acetylation and growth inhibition (Donohoe et al., 2012).
[0127] The effects of butyrate in the later stages of pancreatic differentiation remain unclear, highlighting the importance of this study in investigating the potential effects of butyrate-containing SCFAs in the final stages of pancreatic differentiation. Our innovation lies in strategically shifting the timing of butyrate administration to the final maturation stage of pancreatic differentiation. This approach represents a paradigm shift from conventional protocols that emphasize early butyrate supplementation. Introducing butyrate in the later stages of differentiation resulted in improved functional properties without the cytotoxicity observed in the early stages (Figure 2DF, 3B). Interestingly, butyrate administration at stage 6 suppressed insulin mRNA expression while simultaneously promoting insulin secretion (Figure 2E). Recent studies have shown that a single nucleotide polymorphism (SNP) in the 3' untranslated region of the insulin gene promotes the degradation of insulin mRNA in human pancreatic β-cells (van Tienhoven et al., 2025). This process helps alleviate endoplasmic reticulum (ER) stress, resulting in improved β-cell function and enhanced insulin secretion in response to glucose. Further research is needed, but it is thought that the addition of butyrate may also contribute to increased insulin secretion by lowering insulin mRNA levels.
[0128] Previous studies have shown that butyrate alone does not significantly promote pancreatic differentiation in mouse pancreas-derived nestin-positive progenitor cells, but it enhances the differentiation-promoting effect of GLP-1 (Li et al., 2008; Wei et al., 2012). Based on these findings, it is extremely important to investigate whether butyrate similarly enhances GLP-1 activity in human pluripotent stem cell (hPSC)-based pancreatic differentiation systems. Furthermore, we found that combining methionine deficiency treatment before endodermal differentiation (Sim et al., 2022; Sim et al., 2023) with butyrate treatment in the later stages of differentiation improved the GSIS of the resulting β cells compared to the group treated with existing methionine deficiency protocols alone.
[0129] Our discovery that administering butyrate during the final maturation stage promotes pancreatic differentiation represents a significant advance in the field of hPSC-derived pancreatic cell production. This approach addresses the limitations of early-stage butyrate administration in three-dimensional culture systems while maintaining beneficial effects on pancreatic maturation. This innovative methodology has potential applications in both basic research and therapeutic development, advancing our understanding of pancreatic development and providing improved protocols for producing functional pancreatic cells for disease modeling and cell replacement therapy.
[0130] Materials and methods Culture of human PSC strains Human ESC strain MEL1 INS GFP / w hESCs (Micallef et al., 2012) and the human iPSC strain RPChiPS7713G1 (Reprocell) were used. Both ESCs / iPSCs were cultured under feeder-free conditions on cell culture dishes pre-coated with vitronectin (Thermo Fisher) using human iPSC maintenance medium StemFit AK02N (Ajinomoto). After thawing the ESCs / iPSCs in the dishes, 10 μM of the Rho-associated kinase (ROCK) inhibitor Y-27632 (Wako) was added to the medium for 24 hours to prevent apoptosis.
[0131] RNA extraction and PCR, Cultured cells were lysed, and RNA extraction was performed using the Cica Geneus RNA Prep Kit (KANTO CHEMICAL) according to the instructions. The extracted RNA was quantified using nanodrops, reverse transcribed to cDNA using PrimeScript RT Master Mix (Takara, Japan), and quantitative PCR (qPCR) was performed. Quantitative PCR (qPCR) was performed using THUNDERBIRD NEXT SYBR qPCR Mix (Toyobo, Japan), and after 40 amplification cycles, data were collected and analyzed using the CFX Opus 96 Dx Real-Time PCR System. The PCR conditions for SYBR Green detection were 30 seconds of initial denaturation at 95°C, 5 seconds of denaturation at 95°C, and 30 seconds of annealing and extension at 60°C. Each measurement value was quantified using the Ct method. The measurement values were internally normalized to the β-ACTIN expression level and then externally normalized to the measurement values of the control sample. Details of the primers used are as follows. β-ACTIN: Forward primer TGGCACCCAGCACAATGAA, Reverse primer CTAAGTCATAGTCCGCCTAGAAGCA; INS: Forward Primer GAAGCGGCATTGGAAC, Reverse Primer CTGGTTCAAGGGCTTTATTCCATC.
[0132] immunocytochemistry Spheroids were fixed overnight at 4°C in 4% paraformaldehyde in PBS (Nacalai Tesque). Using a CT-Pro20 system (Genostaff Co., Ltd.), paraffin embedding was performed with G-NOX, a proprietary xylene substitute, and the cells were stored at room temperature until sectioning. Thin sections (8 m) were cut using a cryostat and stained on microscope slides. Before immunoassay, the fixed cells were permeabilized with 1% Triton X-100 (Nacalai Tesque) and blocked with 20% Blocking One (Nacalai Tesque, Japan) in PBST (0.1% Tween-20 in PBS). Antibodies were diluted with 20% Blocking One in PBST. The following antibodies were used: rabbit C-peptide (Cell Signaling Technology, 4593, AB_10691857), guinea pig anti-INS (Agilent, IR002, AB_2800361), mouse anti-NKX6.1 (Developmental Studies Hybridoma Bank, F55A10, AB_532378), mouse anti-OCT4 (Santa Cruz Biotechnology, sc-5279, AB_628051), goat PDX1 (R&D Systems, AF2419, AB_355257), goat SOX17 (R&D Systems, AF1924, AB_355060), and Alexa 488 / 568 / 633- conjugate secondary antibody (Invitrogen). All sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (Roche) at 1 g / ml. Positive cells were quantified using Metamorph Image Analysis Software (Molecular Devices).
[0133] C-peptide release assay Differentiated cells were transferred to 1.5 mL tubes and pre-incubated at 37°C for 2 hours in low-glucose (3.0 mM) HKRB buffer (HEPES Krebs-Ringer bicarbonate buffer) supplemented with 0.2% BSA. After pre-incubation, the cells were incubated for a further 1 hour at 37°C in fresh low-glucose HKRB buffer supplemented with 0.2% BSA. Subsequently, the cells were incubated for a further 1 hour at 37°C in high-glucose (20 mM) HKRB buffer containing 0.2% BSA, and the buffer was collected again. The collected supernatant was stored at -30°C until further analysis. After the final incubation, the cells were dissociated into single cells by enzymatic digestion, and the number of cells was counted. C-peptide secretion was quantified using the human C-peptide AlphaLISA kit (PerkinElmer), and the amount of secreted C-peptide was normalized by the number of cells.
[0134] Pancreatic differentiation In the study of human ESCs (Figure 1), differentiation was initiated immediately after freeze-thawing. Undifferentiated hESCs were divided into 5 x 10⁶ 6 Cells / well were plated into a 6-well Corning plate and cultured in M1-E medium at 37°C for 24 hours on an orbital shaker rotating at 95 rpm until spherical. On day 3, the medium was changed to M2 medium and cultured for 3 days. On day 6, the medium was changed to M3 medium and cultured for 1 day. On day 7, the medium was changed to M4 medium and cultured for 5 days. On day 12, the medium was changed to M5 medium and cultured for 8 days. On day 20, the cell spheres were agglutinated again and the medium was switched to M6 medium. The cell spheres were washed with PBS and incubated in TrypLE Select Enzyme (Thermo Fisher Scientific) at 37°C for 30 minutes. Dissociated single cells were counted and 1 x 10⁶ cells per well were cultured in M6 medium + Y27632. 6 Cells were seeded at their normal density into 24-well Elplasia plates (Corning) and cultured statically in a 37°C incubator. The culture medium was changed every 48 hours with M6 medium and cultured until day 31.
[0135] In the human iPSC study (Figures 2 and 3), undifferentiated hiPSCs cultured on two-dimensional plates pre-coated with Synthemax II (Corning) were dissociated and then transferred to 6-well plates (Corning) in 5 × 10⁶ layers. 6 Cells were transplanted into 6-well suspension culture plates at a cell / well density and cultured at 37°C for 24 hours, then sphereized on a 95 rpm rotating orbital shaker. Subsequently, methionine-deficient pretreatment was performed by culturing in StemFit KA01 ((-) Met) medium (Ajinomoto) for 5 hours before endodermal differentiation (Sim et al., 2022). Differentiation was initiated by changing the medium to M1-I medium. Culture from stage 2 to stage 5 was the same as the differentiation of hESCs described above. On day 20, cell spheres were washed with PBS and incubated in TrypLE Select Enzyme for 30 minutes at 37°C. Dissociated single cells were counted and 5 × 10⁶ cells per well were cultured in M6 medium + Y27632. 6 Seeds were seeded at a density of 1 in a 6-well suspension culture plate (Greiner Bio One) and cultured in an incubator at 37°C and 95 rpm. The culture medium was changed every 48 hours with M6 medium and cultured until day 31.
[0136] The pancreatic differentiation protocol shown in Figure 2 consists of the following stages 1-6. In Figure 3, differentiation induction was performed using the method described in Velazco-Cruz et al., Stem Cell Reports, Vol. 12, 351-365, February 12, 2019, and SCFA was added to the culture medium for Stage 6.
[0137] Stage 1 (M1-E medium for hESCs)Differentiation was initiated using M1-E, which consisted of StemFit AK(IGF) medium supplemented with 3 μM CHIR99021, 100 ng / mL recombinant human Activin-A (Ajinomoto), 10 μM Y27632, and 2 μg / mL DNase (Worthington). The AK(IGF) medium was prepared by adding 100 ng / mL IGF1 to AK(zinc-free) medium (Ajinomoto). On days 1 and 2, the medium was replaced with the same medium without Y27632 and CHIR99021, and the IGF1 concentration was reduced from 100 ng / mL to 10 ng / mL.
[0138] Stage 1 (M1-I medium in the case of hiPSC) The culture medium was changed to MCDB 131 (Gibco) supplemented with 0.44 g / L glucose (Otsuka Pharmaceutical Co., Ltd.), 0.5% FAF-BSA (Proliant Biologicals), 0.002% ITS-X (Gibco), 14.6 mM NaHCO3, and 2 mM L-glutamine (L-Glu), and differentiation was started. 0.002% ITS-X (Gibco), 14.6 mM NaHCO3, 2 mM L-glutamine (L-Glu), 100 U / mL penicillin-streptomycin (PS), 3 μM CHIR99021, 100 ng / mL recombinant human activin-A, and 10 μM Y27632 were added. On days 1 and 2, the medium was changed to Stage 1 (DE) medium without CHIR99021 and Y27632.
[0139] Stage 2 (M2 medium) On days 3 and 5, the culture medium was replaced with MCDB 131 supplemented with 0.44 g / L glucose, 0.5% FAF-BSA, 0.002% ITS-X, 14.6 mM NaHCO3, L-Glu, PS, 50 ng / mL KGF (Fujifilm-Wako), and 44 μg / mL vitamin C (Sigma).
[0140] Stage 3 (M3 medium)On day 6, the culture medium was replaced with MCDB 131 supplemented with 0.44 g / L glucose, 0.5% FAF-BSA, 0.5% ITS-X, 14.6 mM NaHCO3, L-Glu, PS, 50 ng / mL KGF, 0.25 μM SANT-1, 500 nM PdBU, 1 nM LDN193189, 2 μM RA, 44 μg / mL vitamin C, and 10 μM Y27632.
[0141] Stage 4 (M4 medium) From day 7 to day 11, cells were cultured in MCDB 131 supplemented with 0.44 g / L glucose, 0.5% FAF-BSA, 0.5% ITS-X, 14.6 mM NaHCO3, L-Glu, 50 ng / mL KGF, 0.25 μM SANT-1, 100 nM RA, 44 μg / mL vitamin C, 5 ng / mL activin A, and 10 μM Y27632. The culture medium was replaced with fresh medium on days 9 and 11.
[0142] Stage 5 (M5 medium) From day 12 to day 15, the culture medium consisted of 3.6 g / L glucose, 0.5% FAF-BSA, 0.5% ITS-X, 20.9 mM NaH₂CO₃, L-Glu, PS, 10 μM Alk5i, 1 μM γ-Secretase Inhibitor XXI (GSXXI) (Sigma), 20 ng / mL βcellulin (Pepro Tech, Inc.), 100 nM RA, 44 μg / mL vitamin C, 1 μM GC1 or L-3,3′,5-triiodothyronine (T3), 0.25 μM SANT-1, and 10 μg / mL heparin (Sigma). The medium was replaced with fresh medium on day 14. From day 16 to day 19, cells were cultured in the same medium without SANT-1, and the RA concentration was changed from 100 nM to 4 nM. The medium was replaced with fresh medium on day 18.
[0143] Stage 6 (M6 medium)From day 20, cells were cultured in MCDB131 supplemented with 0.44 g / L glucose, 2% FAF-BSA, 14.6 mM NaHCO3, L-Glu, PS, 1% NEAA, 10 μg / mL heparin, 1 μM ZnSO4, 0.1% trace element A (Corning), and 0.1% trace element B (Corning). The culture medium was changed with fresh medium every other day.
[0144] References Abdel-Haleem, AM, Lewis, NE, Jamshidi, N., Mineta, K., Gao, X., and Gojobori, T. (2017). The Emerging Facets of Non-Cancerous Warburg Effect. Front Endocrinol (Lausanne) 8, 279. Donohoe, DR, Collins, LB, Wali, A., Bigler, R., Sun, W., and Bultman, SJ (2012). The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 48, 612-626. Jiang, J., Au, M., Lu, K., Eshpeter, A., Korbutt, G., Fisk, G., and Majumdar, AS (2007). Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells 25, 1940-1953. Li, L., Lili, R., Hui, Q., Min, W., Xue, W., Xin, S., Jing, L., Yan, L., Yeqiang, L., Fenrong, H., et al. (2008). Combination of GLP-1 and sodium butyrate promote differentiation of pancreatic progenitor cells into insulin-producing cells. Tissue Cell 40, 437-445. Micallef, S.J., Li, X., Schiesser, J.V., Hirst, C.E., Yu, Q.C., Lim, S.M., Nostro, M.C., Elliott, D.A., Sarangi, F., Harrison, L.C., et al. (2012). INS(GFP / w) human embryonic stem cells facilitate isolation of in vitro derived insulin-producing cells. Diabetologia 55, 694-706. Pagliuca, F.W., Millman, J.R., Gurtler, M., Segel, M., Van Dervort, A., Ryu, J.H., Peterson, Q.P., Greiner, D., and Melton, D.A. (2014). Generation of functional human pancreatic beta cells in vitro. Cell 159, 428-439. Ren, M., Yan, L., Shang, C.Z., Cao, J., Li, F.P., Li, J.Y., Cheng, H., and Min, J. (2009). Sodium butyrate and dexamethasone promote exocrine pancreatic gene expression in mouse embryonic stem cells. Acta Pharmacol Sin 30, 1289-1296. Shiraki, N., Shiraki, Y., Tsuyama, T., Obata, F., Miura, M., Nagae, G., Aburatani, H., Kume, K., Endo, F., and Kume, S. (2014). Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell Metab 19, 780-794. Sim, E.Z., Enomoto, T., Shiraki, N., Furuta, N., Kashio, S., Kambe, T., Tsuyama, T., Arakawa, A., Ozawa, H., Yokoyama, M., et al. (2022). Methionine metabolism regulates pluripotent stem cell pluripotency and differentiation through zinc mobilization. Cell Rep 40, 111120. Sim, E.Z., Enomoto, T., Shiraki, N., and Kume, S. (2023). Protocol to generate human pluripotent stem cell-derived pancreatic beta cells through methionine and zinc deprivation. STAR Protoc 4, 102183. van Tienhoven, R., O'Meally, D., Scott, T.A., Morris, K.V., Williams, J.C., Kaddis, J.S., Zaldumbide, A., and Roep, B.O. (2025). Genetic protection from type 1 diabetes resulting from accelerated insulin mRNA decay. Cell. Wang, S., Yuan, M., Zhang, L., Zhu, K., Sheng, C., Zhou, F., Xu, Z., Liu, Q., Liu, Y., Lu, J., et al. (2022). Sodium butyrate potentiates insulin secretion from rat islets at the expense of compromised expression of beta cell identity genes. Cell Death Dis 13, 67. Wei, P., Li, L., Qi, H., Zhou, H.X., Deng, C.Y., and Li, F.R. (2012). Reversible immortalization of Nestin-positive precursor cells from pancreas and differentiation into insulin-secreting cells. Biochem Biophys Res Commun 418, 330-335. Zhou, Q.J., Xiang, L.X., Shao, J.Z., Hu, R.Z., Lu, Y.L., Yao, H., and Dai, L.C. (2007). In vitro differentiation of hepatic progenitor cells from mouse embryonic stem cells induced by sodium butyrate. J Cell Biochem 100, 29-42. [Industrial applicability]
[0145] The present invention enables more efficient differentiation of pluripotent stem cells, such as ES cells and iPS cells, into insulin-producing β-cells. Insulin-producing β-cells produced by the method of the present invention can be used for screening compounds useful for the prevention and / or treatment of diseases such as diabetes.
Claims
1. A method for producing insulin-producing β-cells, The method comprising bringing immature insulin-expressing β-cells into contact with butyrate to induce maturation into insulin-producing β-cells.
2. The method according to claim 1, wherein insulin-producing β-cells have improved insulin secretion capacity compared to immature β-cells.
3. The method according to claim 1 or 2, wherein immature β-cells expressing insulin are differentiated from pluripotent stem cells.
4. The method according to claim 3, wherein the pluripotent stem cells are ES cells and / or iPS cells.
5. The method according to any one of claims 1 to 4, wherein the immature β-cells expressing insulin are of human origin.
6. The method according to any one of claims 1 to 5, wherein immature β-cells expressing insulin are cultured in a butyrate-containing medium.
7. The method according to claim 6, wherein the culture is a three-dimensional culture.
8. Insulin-producing β-cells prepared by any of claims 1 to 7, which can secrete 0.1 pg / min / 1000 cells or more of C-peptide under conditions where the glucose concentration is 20 mM.
9. A culture medium for maturing immature β cells into insulin-producing β cells, the culture medium containing butyric acid.
